NCT06559878View on ClinicalTrials.gov

Hepatic Mitochondrial Metabolism in Fatty Liver Disease in Humans

NAEnrolling by invitationINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

January 31, 2027

Conditions
Non-alcoholic Fatty Liver Disease NAFLD
Interventions
DIAGNOSTIC_TEST

13C-α-Ketoisocaproic Acid Breath Test

13C-α-Ketoisocaproic acid with L-Leucine soluted in citric acid drink. The solution is administered orally during metabolic visits (3.-5.).

DIETARY_SUPPLEMENT

Ethanol

6% ethanol soluted in normal saline is given intravenously during one metabolic visit.

DIETARY_SUPPLEMENT

Lipid Emulsion

Lipid emulsion, heparin and normal saline are given intravenously during one metabolic visit.

OTHER

Normal Saline

Normal saline is given intravenously during one metabolic visit.

Trial Locations (1)

00290

Helsinki Central University Hospital, Helsinki

All Listed Sponsors
lead

Helsinki University Central Hospital

OTHER